OBJECTIVE: To assess perinatal outcomes with Carpenter-Coustan criteria for gestational diabetes mellitus (GDM), those with normal glucose testing, and those who would be added to GDM by The International Association of the Diabetes and Pregnancy Study Groups (IADPSG) criteria.
METHODS: This was a retrospective cohort study of women who underwent screening and diagnostic testing for GDM. Patients were divided into nonoverlapping groups: GDM by Carpenter-Coustan (Carpenter-Coustan), IADPSG GDM criteria but not Carpenter-Coustan (IADPSG), and normal GDM screening or testing (control). Outcomes included newborn birth weight, birth weight z-score, Ponderal Index, and large for gestational age. Data were analyzed with one-way analysis of variance, t tests, or χ2.
RESULTS: There were 8,390 women who met inclusion criteria: 338 Carpenter-Coustan; 281 IADPSG; and 7,771 women in the control group. Mean birth weight (3,411 compared with 3,240 g, P<.01), birth weight z-score (0.477 compared with 0.059, P<.01), Ponderal Index (2.79 compared with 2.73 g/cm3, P=.014), and large for gestational age (19.9% compared with 8.8%, relative risk 2.25, 95% confidence interval [CI] 1.76–2.88) were higher in IADPSG compared with women in the control group. The IADPSG group had greater birth weight (3,411 compared with 3,288 g, P<.01) than Carpenter-Coustan neonates with no difference in large for gestational age (19.9% compared with 16.0%, relative risk 1.25 95% CI 0.88–1.75), Ponderal Index (2.78 compared with 2.79 g/cm3, P=1), or birth weight z-score (0.477 compared with 0.330, P=.30).
CONCLUSIONS: Newborns of women who would be added to the diagnosis of GDM by IADPSG criteria have greater measures of fetal overgrowth than those in the control group and greater birth weight in comparison with Carpenter-Coustan GDM neonates.
LEVEL OF EVIDENCE: II
Women who would be diagnosed with gestational diabetes under proposed criteria have greater measures of fetal overgrowth than do women without gestational diabetes.
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio; and the Department of Obstetrics and Gynecology, Loyola University Medical Center, Maywood, Illinois.
Corresponding author: John K. Ethridge, Jr, MD, Instructor of Reproductive Biology, Case Western Reserve University, Suite G240, Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland, OH 44109; e-mail: email@example.com.
Presented at the 73rd Scientific Sessions of the American Diabetes Association, June 21–25, 2013, Chicago, Illinois.
Financial Disclosure The authors did not report any potential conflicts of interest.